Palisade Bio: Didn’t Start Strong With Blockbuster, Estimated Purchase Ratings
Lifescience Investor focuses on unconventional short-term investment ideas. I focus on small to mid-sized publicly traded biotechnology companies in the US and EU markets. I like to explore clinical catalysts or play revenue through new drug launches. I do not give personal investment advice. All content I provide, including but not limited to opinions, analysis, commentary, forecasts, stock selection, and investment strategies, is for informational and educational purposes only and should not be construed as financial or investment advice. Although I strive to provide accurate and up-to-date information, the content may contain errors, mistakes, or omissions. Any financial decisions or investments made based on the information presented in this article are at your sole risk. I am not responsible for any financial loss, damage, or other consequences resulting from actions taken in reliance on the information provided. You should exercise caution and consult with a qualified financial professional before making any investment decisions. This article reflects my personal views and opinions and is not affiliated with any employer, financial institution, or advisory firm. No representations or warranties are made about the completeness, accuracy, or reliability of the content, including any external links provided. Any links to third parties are for informational purposes only, and I do not endorse or take responsibility for the content or services provided by such third party sources. All information is provided “as is” without express or implied warranties.
Analyst disclosure: I/we have a long beneficial position in PALI shares through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my opinions. I get no compensation for it (other than Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
I do not give personal investment advice. All content in this article, including but not limited to opinions, analysis, commentary, forecasts, stock selection, and investment strategies, is for informational and educational purposes only and should not be construed as financial or investment advice. Although I strive to provide accurate and up-to-date information, the content may contain errors, mistakes, or omissions. Any financial decisions or investments made based on the information presented in this article are at your sole risk. I am not responsible for any financial loss, damage, or other consequences resulting from actions taken in reliance on the information provided. You should do your own due diligence and consult with a qualified financial professional before making any investment decisions. This article reflects my personal views and opinions and is not affiliated with any employer, financial institution, or advisory firm. No representations or warranties are made about the completeness, accuracy, or reliability of the content, including any external links provided. Any links to third parties are for informational purposes only, and I do not endorse or take responsibility for the content or services provided by such third party sources. All information is provided “as is” without express or implied warranties.
Seeking Alpha Disclosure: Past performance is no guarantee of future results. No recommendation or advice is given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not necessarily reflect those of Seeing Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third-party underwriters that include both professional investors and individual investors who may not be licensed or certified by any institution or regulatory body.
